Cetuximab represents an IgG1 monoclonal antibody against the ligand-binding domain of the abnormally activated and overexpressed epidermal growth factor receptor (EGFR) [18], thus down-regulating tumor growth and improving the cytotoxic effect of radiation [12,18]. The gene discussed is EGFR; the disease is neoplasm.